Meningitis is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Meningitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Meningitis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Meningitis overview
Meningitis is the inflammation of the meninges, protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life-threatening, depending on its cause. Viral meningitis is not life-threatening; those affected can be recover quickly. Bacterial meningitis is serious and life-threatening. The three major bacteria are Neisseria meningitides, which causes meningococcal meningitis; pneumococcal meningitis is caused by the bacteria streptococcus pneumonia; and haemophilius influenza causes meningitis in infants. 44–46% of cases of bacterial meningitis have all of the following three symptoms: severe headache, nuchal ridgidity (inability to flex the neck forward), and altered mental status. Severe headache occurs in 90% of the cases. Other symptoms include photophobia (fear of bright light) and phonophobia (fear of loud noises). In infants up to 6 months, bulging of the fontanelle (soft spot on the baby’s head) may be visible. Less severe symptoms, including extreme cold, abnormality in skin color, and leg pain, may also be distinguishing features for meningitis.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Meningitis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
